ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1TSLA | TESLA INC | Consumer Cyclical | $1.57T | 17.98% |
2LLY | ELI LILLY & CO | Healthcare | $1.34T | 15.37% |
3JNJ | JOHNSON & JOHNSON | Healthcare | $682.52B | 7.81% |
4ABBV | ABBVIE INC | Healthcare | $520.47B | 5.96% |
5KO | COCA COLA CO | Consumer Defensive | $419.18B | 4.80% |
6MRK | MERCK & CO INC | Healthcare | $362.27B | 4.15% |
7NFLX | NETFLIX INC | Communication Services | $257.43B | 2.95% |
8AMGN | AMGEN INC | Healthcare | $252.64B | 2.89% |
9GILD | GILEAD SCIENCES INC | Healthcare | $208.31B | 2.38% |
10DIS | WALT DISNEY CO | Communication Services | $204.15B | 2.34% |
11PEP | PEPSICO INC | Consumer Defensive | $193.86B | 2.22% |
12ABT | ABBOTT LABORATORIES | Healthcare | $185.75B | 2.13% |
13PFE | PFIZER INC | Healthcare | $164.33B | 1.88% |
14VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $137.57B | 1.57% |
15BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 1.46% |
16REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 1.13% |
17WM | WASTE MANAGEMENT INC | Industrials | $97.07B | 1.11% |
18MRNA | MODERNA INC | Healthcare | $93.61B | 1.07% |
19RSG | REPUBLIC SERVICES INC | Industrials | $77.07B | 0.88% |
20GM | GENERAL MOTORS CO | Consumer Cyclical | $72.76B | 0.83% |
21PCAR | PACCAR INC | Industrials | $55.98B | 0.64% |
22IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 0.63% |
23TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $50.93B | 0.58% |
24WCN | WASTE CONNECTIONS INC | Industrials | $48.51B | 0.56% |
25KDP | KEURIG DR PEPPER INC | Consumer Defensive | $48.20B | 0.55% |
26F | FORD MOTOR CO | Consumer Cyclical | $47.52B | 0.54% |
27ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 0.54% |
28LYV | LIVE NATION ENTERTAINMENT INC | Communication Services | $42.46B | 0.49% |
29RPRX | ROYALTY PHARMA PLC | Healthcare | $39.56B | 0.45% |
30CBRE | CBRE GROUP INC | Real Estate | $38.20B | 0.44% |
31RVMD | REVOLUTION MEDICINES INC | Healthcare | $38.14B | 0.44% |
32BIIB | BIOGEN INC | Healthcare | $37.03B | 0.42% |
33TKO | TKO GROUP HOLDINGS INC | Communication Services | $36.60B | 0.42% |
34ZTS | ZOETIS INC | Healthcare | $33.71B | 0.39% |
35ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 0.33% |
36INSM | INSMED INC | Healthcare | $25.90B | 0.30% |
37UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 0.29% |
38STZ | CONSTELLATION BRANDS INC | Consumer Defensive | $24.47B | 0.28% |
39VTRS | VIATRIS INC | Healthcare | $23.70B | 0.27% |
40ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $20.98B | 0.24% |
41RIVN | RIVIAN AUTOMOTIVE INC | Consumer Cyclical | $18.68B | 0.21% |
42NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 0.20% |
43JLL | JONES LANG LASALLE INC | Real Estate | $16.70B | 0.19% |
44WMG | WARNER MUSIC GROUP CORP | Communication Services | $16.57B | 0.19% |
45CLH | CLEAN HARBORS INC | Industrials | $15.49B | 0.18% |
46JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.43B | 0.18% |
47INVH | INVITATION HOMES INC | Real Estate | $15.35B | 0.18% |
48BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.23B | 0.17% |
49BF.B | BROWN FORMAN CORP | Consumer Defensive | $13.78B | 0.16% |
50ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $13.25B | 0.15% |
51SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $12.06B | 0.14% |
52HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.13% |
53TECH | BIO-TECHNE CORP | Healthcare | $11.44B | 0.13% |
54BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $10.98B | 0.13% |
55KYMR | KYMERA THERAPEUTICS INC | Healthcare | $10.86B | 0.12% |
56RGEN | REPLIGEN CORP | Healthcare | $10.64B | 0.12% |
57AES | AES CORP | Utilities | $10.64B | 0.12% |
58ALSN | ALLISON TRANSMISSION HOLDINGS INC | Consumer Cyclical | $10.32B | 0.12% |
59PCVX | VAXCYTE INC | Healthcare | $10.24B | 0.12% |
60BWA | BORGWARNER INC | Consumer Cyclical | $10.24B | 0.12% |
61LTH | LIFE TIME GROUP HOLDINGS INC | Consumer Cyclical | $10.23B | 0.12% |
62MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $9.88B | 0.11% |
63SYRE | SPYRE THERAPEUTICS INC | Healthcare | $9.77B | 0.11% |
64TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 0.11% |
65LLYVA | LIBERTY LIVE HOLDINGS INC | Communication Services | $9.58B | 0.11% |
66DKNG | DRAFTKINGS INC | Consumer Cyclical | $9.53B | 0.11% |
67PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $9.08B | 0.10% |
68KRYS | KRYSTAL BIOTECH INC | Healthcare | $9.06B | 0.10% |
69PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 0.10% |
70OSK | OSHKOSH CORP | Industrials | $8.56B | 0.10% |
71ALV | AUTOLIV INC | Consumer Cyclical | $8.56B | 0.10% |
72CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 0.09% |
73ALKS | ALKERMES PLC | Healthcare | $7.89B | 0.09% |
74CYTK | CYTOKINETICS INC | Healthcare | $7.82B | 0.09% |
75RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.62B | 0.09% |
76MSGK | MSG KNICKERBOCKERS CORP | Communication Services | $7.60B | 0.09% |
77AXSM | AXSOME THERAPEUTICS INC | Healthcare | $7.59B | 0.09% |
78KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 0.09% |
79AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 0.09% |
80TRNO | TERRENO REALTY CORP | Real Estate | $7.34B | 0.08% |
81IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 0.08% |
82TWST | TWIST BIOSCIENCE CORP | Healthcare | $7.16B | 0.08% |
83ORKA | ORUKA THERAPEUTICS INC | Healthcare | $7.12B | 0.08% |
84FSS | FEDERAL SIGNAL CORP | Industrials | $7.02B | 0.08% |
85TAP | MOLSON COORS BEVERAGE CO | Consumer Defensive | $6.95B | 0.08% |
86CHDN | CHURCHILL DOWNS INC | Consumer Cyclical | $6.83B | 0.08% |
87KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 0.08% |
88RIOT | RIOT PLATFORMS INC | Financial Services | $6.69B | 0.08% |
89ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $6.66B | 0.08% |
90LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 0.08% |
91TEX | TEREX CORP | Industrials | $6.47B | 0.07% |
92IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 0.07% |
93CWST | CASELLA WASTE SYSTEMS INC | Industrials | $6.38B | 0.07% |
94LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.33B | 0.07% |
95CGON | CG ONCOLOGY INC | Healthcare | $6.27B | 0.07% |
96MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $6.09B | 0.07% |
97MANE | VERADERMICS INC | Healthcare | $5.71B | 0.07% |
98MOD | MODINE MANUFACTURING CO | Consumer Cyclical | $5.64B | 0.06% |
99ERAS | ERASCA INC | Healthcare | $5.52B | 0.06% |
100MTN | VAIL RESORTS INC | Consumer Cyclical | $5.39B | 0.06% |
101PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 0.06% |
102SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 0.06% |
103LEA | LEAR CORP | Consumer Cyclical | $5.23B | 0.06% |
104DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.21B | 0.06% |
105COGT | COGENT BIOSCIENCES INC | Healthcare | $5.07B | 0.06% |
106EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.06% |
107TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $4.95B | 0.06% |
108CNK | CINEMARK HOLDINGS INC | Communication Services | $4.80B | 0.05% |
109ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $4.77B | 0.05% |
110ATMU | ATMUS FILTRATION TECHNOLOGIES INC | Industrials | $4.53B | 0.05% |
111DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.52B | 0.05% |
112SPHR | SPHERE ENTERTAINMENT CO | Communication Services | $4.49B | 0.05% |
113PLNT | PLANET FITNESS INC | Consumer Cyclical | $4.48B | 0.05% |
114MRP | MILLROSE PROPERTIES INC | Real Estate | $4.26B | 0.05% |
115TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.21B | 0.05% |
116LION | LIONSGATE STUDIOS CORP | Communication Services | $4.20B | 0.05% |
117CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.13B | 0.05% |
118XENE | XENON PHARMACEUTICALS INC | Healthcare | $4.03B | 0.05% |
119JOE | ST JOE CO | Real Estate | $4.02B | 0.05% |
120RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 0.05% |
121THO | THOR INDUSTRIES INC | Consumer Cyclical | $3.99B | 0.05% |
122GNTX | GENTEX CORP | Consumer Cyclical | $3.98B | 0.05% |
123GTX | GARRETT MOTION INC | Consumer Cyclical | $3.97B | 0.05% |
124VAC | MARRIOTT VACATIONS WORLDWIDE CORP | Consumer Cyclical | $3.96B | 0.05% |
125DORM | DORMAN PRODUCTS INC | Consumer Cyclical | $3.89B | 0.04% |
126AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $3.84B | 0.04% |
127ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 0.04% |
128TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.04% |
129IRON | DISC MEDICINE INC | Healthcare | $3.79B | 0.04% |
130MSGE | MADISON SQUARE GARDEN ENTERTAINMENT CORP | Consumer Cyclical | $3.74B | 0.04% |
131BATRA | ATLANTA BRAVES HOLDINGS INC | Communication Services | $3.70B | 0.04% |
132COCO | VITA COCO COMPANY INC | Consumer Defensive | $3.69B | 0.04% |
133PII | POLARIS INC | Consumer Cyclical | $3.68B | 0.04% |
134OGN | ORGANON & CO | Healthcare | $3.65B | 0.04% |
135CURB | CURBLINE PROPERTIES CORP | Real Estate | $3.56B | 0.04% |
136ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.56B | 0.04% |
137IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $3.53B | 0.04% |
138ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.48B | 0.04% |
139CWK | CUSHMAN & WAKEFIELD LTD | Real Estate | $3.17B | 0.04% |
140ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 0.04% |
141BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.04% |
142OSW | ONESPAWORLD HOLDINGS LTD | Consumer Cyclical | $3.07B | 0.04% |
143IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.04B | 0.03% |
144XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $3.04B | 0.03% |
145ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.03% |
146VCEL | VERICEL CORP | Healthcare | $2.93B | 0.03% |
147XNCR | XENCOR INC | Healthcare | $2.86B | 0.03% |
148RSI | RUSH STREET INTERACTIVE INC | Consumer Cyclical | $2.72B | 0.03% |
149MBX | MBX BIOSCIENCES INC | Healthcare | $2.71B | 0.03% |
150UE | URBAN EDGE PROPERTIES | Real Estate | $2.66B | 0.03% |
151PHIN | PHINIA INC | Consumer Cyclical | $2.61B | 0.03% |
152NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.03% |
153LCII | LCI INDUSTRIES | Consumer Cyclical | $2.36B | 0.03% |
154SDGR | SCHRODINGER INC | Healthcare | $2.32B | 0.03% |
155DAN | DANA INC | Consumer Cyclical | $2.27B | 0.03% |
156PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.03% |
157CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.24B | 0.03% |
158SAM | BOSTON BEER CO INC | Consumer Defensive | $2.23B | 0.03% |
159IMNM | IMMUNOME INC | Healthcare | $2.21B | 0.03% |
160AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.17B | 0.02% |
161PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.02% |
162SUPN1 | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.11B | 0.02% |
163REPL | REPLIMUNE GROUP INC | Healthcare | $2.08B | 0.02% |
164VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.02% |
165MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.02% |
166SEPN | SEPTERNA INC | Healthcare | $1.99B | 0.02% |
167HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.02% |
168BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 0.02% |
169MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.97B | 0.02% |
170VC | VISTEON CORP | Consumer Cyclical | $1.95B | 0.02% |
171NMRK | NEWMARK GROUP INC | Real Estate | $1.95B | 0.02% |
172TRVI | TREVI THERAPEUTICS INC | Healthcare | $1.94B | 0.02% |
173STUB | STUBHUB HOLDINGS INC | Communication Services | $1.93B | 0.02% |
174TRLV | TRULIEVE CANNABIS CORP | Healthcare | $1.90B | 0.02% |
175GTY | GETTY REALTY CORP | Real Estate | $1.90B | 0.02% |
176ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.02% |
177PRKS | UNITED PARKS & RESORTS INC | Consumer Cyclical | $1.82B | 0.02% |
178ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.02% |
179BLBD | BLUE BIRD CORP | Consumer Cyclical | $1.76B | 0.02% |
180QURE | UNIQURE NV | Healthcare | $1.73B | 0.02% |
181SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.02% |
182NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.02% |
183SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.02% |
184ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.02% |
185IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.02% |
186RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $1.53B | 0.02% |
187THRM | GENTHERM INC | Consumer Cyclical | $1.51B | 0.02% |
188PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.02% |
189IIPR | INNOVATIVE INDUSTRIAL PROPERTIES INC | Real Estate | $1.45B | 0.02% |
190PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.02% |
191ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.02% |
192KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.02% |
193LBRX | LB PHARMACEUTICALS INC | Healthcare | $1.37B | 0.02% |
194MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $1.37B | 0.02% |
195TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.37B | 0.02% |
196DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.36B | 0.02% |
197INVA | INNOVIVA INC | Healthcare | $1.35B | 0.02% |
198OMER | OMEROS CORP | Healthcare | $1.30B | 0.01% |
199URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.01% |
200INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.01% |
201PDM | PIEDMONT REALTY TRUST INC | Real Estate | $1.23B | 0.01% |
202AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.01% |
203ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.01% |
204ADNT | ADIENT PLC | Consumer Cyclical | $1.22B | 0.01% |
205VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.01% |
206FUN | SIX FLAGS ENTERTAINMENT CORPORATION | Consumer Cyclical | $1.14B | 0.01% |
207FOR | FORESTAR GROUP INC | Real Estate | $1.13B | 0.01% |
208ACEL | ACCEL ENTERTAINMENT INC | Consumer Cyclical | $1.11B | 0.01% |
209HROW | HARROW INC | Healthcare | $1.06B | 0.01% |
210CYRX | CRYOPORT INC | Industrials | $1.02B | 0.01% |
211SMP | STANDARD MOTOR PRODUCTS INC | Consumer Cyclical | $982M | 0.01% |
212MMI | MARCUS & MILLICHAP INC | Real Estate | $920M | 0.01% |
213CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $896M | 0.01% |
214WGO | WINNEBAGO INDUSTRIES INC | Consumer Cyclical | $883M | 0.01% |
215RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $860M | 0.01% |
216MCS | MARCUS CORP | Communication Services | $846M | 0.01% |
217MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.01% |
218WEST | WESTROCK COFFEE CO | Consumer Defensive | $841M | 0.01% |
219FUBO | FUBOTV INC | Communication Services | $838M | 0.01% |
220AEVA | AEVA TECHNOLOGIES INC | Consumer Cyclical | $825M | 0.01% |
221CTO | CTO REALTY GROWTH INC | Real Estate | $785M | 0.01% |
222COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.01% |
223QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.01% |
224JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 0.01% |
225NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.01% |
226QUIT | ACHIEVE LIFE SCIENCES INC | Healthcare | $692M | 0.01% |
227SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $679M | 0.01% |
228FBYD | FALCON'S BEYOND GLOBAL INC | Industrials | $678M | 0.01% |
229DSGN | DESIGN THERAPEUTICS INC | Healthcare | $678M | 0.01% |
230RSVR | RESERVOIR MEDIA INC | Communication Services | $675M | 0.01% |
231ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $664M | 0.01% |
232CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.01% |
233CLYM | CLIMB BIO INC | Healthcare | $639M | 0.01% |
234SRZN | SURROZEN INC | Healthcare | $604M | 0.01% |
235IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.01% |
236MLR | MILLER INDUSTRIES INC | Consumer Cyclical | $551M | 0.01% |
237MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.01% |
238TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.01% |
239PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.01% |
240DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.01% |
241HY | HYSTER-YALE INC | Industrials | $501M | 0.01% |
242MNPR | MONOPAR THERAPEUTICS | Healthcare | $488M | 0.01% |
243GOOD | GLADSTONE COMMERCIAL CORP | Real Estate | $479M | 0.01% |
244HPP | HUDSON PACIFIC PROPERTIES INC | Real Estate | $478M | 0.01% |
245WNC | WABASH NATIONAL CORP | Industrials | $477M | 0.01% |
246EOLS | EVOLUS INC | Healthcare | $475M | 0.01% |
247AHRT | AH REALTY TRUST INC | Real Estate | $468M | 0.01% |
248TRC | TEJON RANCH CO | Industrials | $467M | 0.01% |
249STRZ | STARZ ENTERTAINMENT CORP | Communication Services | $454M | 0.01% |
250PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.00% |
251PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.00% |
252BOC | BOSTON OMAHA CORP | Communication Services | $413M | 0.00% |
253ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $411M | 0.00% |
254FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.00% |
255ARL | AMERICAN REALTY INVESTORS INC | Real Estate | $370M | 0.00% |
256EMBC | EMBECTA CORP | Healthcare | $364M | 0.00% |
257FRPH | FRP HOLDINGS INC | Real Estate | $354M | 0.00% |
258PESI | PERMA FIX ENVIRONMENTAL SERVICES INC | Industrials | $331M | 0.00% |
259ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.00% |
260CHPT | CHARGEPOINT HOLDINGS INC | Consumer Cyclical | $324M | 0.00% |
261CPS | COOPER-STANDARD HOLDINGS INC | Consumer Cyclical | $323M | 0.00% |
262BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.00% |
263TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.00% |
264EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.00% |
265MLP | MAUI LAND & PINEAPPLE CO INC | Real Estate | $299M | 0.00% |
266ENHA | ENHANCED GROUP INC | Consumer Defensive | $279M | 0.00% |
267QTTB | Q32 BIO INC | Healthcare | $264M | 0.00% |
268SEG | SEAPORT ENTERTAINMENT GROUP INC | Real Estate | $263M | 0.00% |
269STRT | STRATTEC SECURITY CORP | Consumer Cyclical | $251M | 0.00% |
270LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.00% |
271BRCC | BRC INC | Consumer Defensive | $241M | 0.00% |
272USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $235M | 0.00% |
273GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.00% |
274CPSS | CONSUMER PORTFOLIO SERVICES INC | Financial Services | $214M | 0.00% |
275NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $178M | 0.00% |
276NEN | NEW ENGLAND REALTY ASSOCIATES LIMITED PARTNERSHIP | Real Estate | $158M | 0.00% |
277MPAA | MOTORCAR PARTS OF AMERICA INC | Consumer Cyclical | $146M | 0.00% |
278SRI | STONERIDGE INC | Consumer Cyclical | $145M | 0.00% |
279SKIN | SKINHEALTH SYSTEMS INC | Consumer Defensive | $104M | 0.00% |
280CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.00% |
281ICCC | IMMUCELL CORP | Healthcare | $93M | 0.00% |
282INTG | INTERGROUP CORP | Consumer Cyclical | $86M | 0.00% |
283MAYS | MAYS J W INC | Real Estate | $85M | 0.00% |
284RLYB | RALLYBIO CORP | Healthcare | $84M | 0.00% |
285CPHC | CANTERBURY PARK HOLDING CORP | Consumer Cyclical | $81M | 0.00% |
286FTLF | FITLIFE BRANDS INC | Consumer Defensive | $78M | 0.00% |
287LFVN | LIFEVANTAGE CORP | Consumer Defensive | $64M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $8.74T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Days required to liquidate the largest position at 20% of one day's dollar volume.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 287 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 12.7% | 8.2% |
| 3 yearsp.a. | 14.5% | -2.9% |
| 5 yearsp.a. | 9.8% | 2.6% |
| 10 yearsp.a. | 14.3% | 7.2% |
| Since inceptionp.a. | 8.8% | 3.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 14.0% | 10.2% |
| 2025 | 17.9% | 2.2% |
| 2024 | 8.7% | -10.1% |
| 2023 | 0.1% | -14.0% |
| 2022 | 1.9% | 24.1% |
| 2021 | 19.7% | -3.8% |
| 2020 | 35.3% | 42.2% |
| 2019 | 14.7% | -5.8% |
| 2018 | 7.0% | 21.3% |
| 2017 | 28.1% | 21.2% |
| 2016 | 0.4% | -18.0% |
| 2015 | 5.5% | 24.3% |
| 2014 | 18.3% | 23.7% |
| 2013 | 36.6% | 5.9% |
| 2012 | 21.7% | -2.6% |
| 2011 | -1.1% | 5.0% |
| 2010 | 23.7% | 11.5% |
| 2009 | 40.0% | 18.0% |
| 2008 | -53.1% | -11.4% |
| 2007 | -9.1% | 6.0% |
| 2006 | 20.8% | 6.7% |
| 2005 | 7.4% | 2.6% |
| 2004 | 11.1% | -8.6% |
| 2003 | 28.6% | -8.3% |
| 2002 | -24.0% | -9.1% |
| 2001 | -7.9% | 2.3% |
| 2000 | 25.8% | 32.2% |
| 1999 | 12.5% | -33.2% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry OCFP Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a OCFP signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,140-name universe at November 2026. Rows: Large ≥ $5.3B, Small < $832M. Columns: Value ≥ 0.62, Growth < 0.33 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 86% toward Growth. +4% unclassified (39 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 287 names now. Hypothetical holdings — descriptive, not P&L.